Mineralys Therapeutics Inc’s recently made public that its Officer Rodman David Malcom acquired Company’s shares for reported $9.38 million on Jan 02 ’26. In the deal valued at $35.71 per share,262,752 shares were bought.
Then, Slingsby Brian Taylor sold 1,000,000 shares, generating $43,350,000 in total proceeds. Upon selling the shares at $43.35, the Director now owns 7,903,838 shares.
Before that, Catalys Pacific Fund, LP bought 1,000,000 shares. Mineralys Therapeutics Inc shares valued at $42,120,000 were divested by the Affiliate at a price of $42.12 per share.
Jefferies initiated its Mineralys Therapeutics Inc [MLYS] rating to a Hold in a research note published on June 11, 2025; the price target was $15. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in early July with a ‘”a Buy”‘ rating. Goldman began covering MLYS with “Buy” recommendation on April 02, 2024. Wells Fargo started covering the stock on March 07, 2023. It rated MLYS as “an Overweight”.
Price Performance Review of MLYS
On Monday, Mineralys Therapeutics Inc [NASDAQ:MLYS] saw its stock fall -0.14% to $35.66. Over the last five days, the stock has lost -3.98%. Mineralys Therapeutics Inc shares have risen nearly 189.68% since the year began. Nevertheless, the stocks have fallen -1.74% over the past one year. While a 52-week high of $47.65 was reached on 01/02/26, a 52-week low of $8.24 was recorded on 01/05/26.
Levels Of Support And Resistance For MLYS Stock
The 24-hour chart illustrates a support level at 34.66, which if violated will result in even more drops to 33.65. On the upside, there is a resistance level at 36.22. A further resistance level may holdings at 36.77.
How much short interest is there in Mineralys Therapeutics Inc?
A steep rise in short interest was recorded in Mineralys Therapeutics Inc stocks on 2025-12-15, growing by 1.06 million shares to a total of 7.95 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-14 was 6.89 million shares. There was a rise of 13.32%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 07, 2023 when Stifel began covering the stock and recommended ‘”a Buy”‘ rating along with a $45 price target.
